Oslo, August 22, 2025 - Observe Medical ("the Company" or "Observe Medical") today releases its results for the first half of 2025. The Company will host a presentation with a trading update Tuesday, 23 September 2025.

Financial highlights

• Operating revenues amounted to NOK 11.3 million, supported by a 61% increase in sales of the UnoMeter™ product family YoY driven by the introduction of UnoMeter™ Safeti™ Plus, offset by the discontinuation of the Nordic distribution business
• Operating result before depreciation and amortisation (EBITDA) of negative NOK 8.7 million, an improvement of 3.9 million YoY 
• Result of negative NOK 19.0 million, an improvement of NOK 6.4 million YoY

During the first half year, the first major shipments of UnoMeter™ Safeti Plus reached distributors across Europe, the Middle East, and Asia, re-establishing sales in key markets. The product has received orders from a broad range of countries, with multiple repeat orders confirming strong market acceptance.

Subsequent events

• July 3 2025, the Company successfully completed a private placement of new shares in the Company to raise gross proceeds of NOK 36.4 million, to be followed by a subsequent offering.
• The Group has, through negotiations and restructuring of debt, reduced its total debt by approximately NOK 50 million and at the same time closed the asset transfer agreement, enabling the transfer of all UnoMeter™ associated assets to the Group.

Observe Medical invites investors, analysts, and other stakeholders to a presentation and trading update 23 September 2025. Details regarding the time and venue will be announced when available.

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells innovative medtech products for the global market. The Company is committed to improving patient welfare and patient outcomes, improving clinical data accuracy and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and commercialization of its broad portfolio of medical technology products, mainly in urine measurement and ultrasound, in combination with targeted M&A and distribution. Observe Medical is working with a network of leading distributors to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.